Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $34.85 | Total: $174.25 |
| 1 | 10 | $29.52 | Total: $295.20 |
| 1 | 25 | $25.01 | Total: $625.25 |
| 1 | 50 | $21.32 | Total: $1,066.00 |
| 1 | 100 | $18.45 | Total: $1,845.00 |
Overview
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Chemical Properties
| Molecular Formula | C22H15F3N2O7S |
| Molecular Weight | 508.42 |
| CAS Numbers | 935283-04-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Ezzati M, Carr BR [2015].